Cedar Global Markets
Subscribe
SAVED POSTS
  • Login
No Result
View All Result
  • Home
  • Markets
  • Economy
  • Business
  • Energy
  • Technology
  • Global
    • Middle East
    • Europe
    • Asia-Pacific
    • Americas
    • Africa
  • Opinion
No Result
View All Result
  • Home
  • Markets
  • Economy
  • Business
  • Energy
  • Technology
  • Global
    • Middle East
    • Europe
    • Asia-Pacific
    • Americas
    • Africa
  • Opinion
Cedar Global Markets
US 2Y4.88%
US 10Y5.15%
US 30Y5.47%
2s10s+27bp
WTI$89.62
Brent$92.14
Fed funds3.75–4.00%
CPI3.7% YoY
Core CPI2.6% YoY
Unemployment4.1%
Cedar Global MarketsData via FRED® (St. Louis Fed). Not endorsed by the St. Louis Fed. Delayed / as published.

Tyson Foods Jumps 6% After Its Year-End Report and a Dividend Increase

in Business, Americas
Reading Time: 4 mins read
Line chart of Tyson Foods' daily closing share price since Aug. 3, 2026, with a jump of 6.3% to $62.55 at 2:20 p.m. Eastern time on Monday, Nov. 16, from $58.82 at Friday's close, beside bars showing fiscal fourth-quarter adjusted earnings per share falling 47% to $0.61 from $1.15.
byCedar Global Markets
November 16, 2026
0
Share on Facebook
Share on X

Tyson Foods shares rose about 6% on Monday after the meat company reported results for its fiscal fourth quarter and raised its dividend. The stock traded at $62.55 at 2:20 p.m. Eastern time, up $3.73, or 6.3%, from Friday’s close of $58.82.

For the quarter ended Oct. 3, sales rose 5.2% to $14.59 billion, helped by an extra week in the period. Adjusted earnings fell 47% to 61 cents a share from $1.15 a year earlier, and under standard accounting rules Tyson lost 22 cents a share. Its beef business posted an operating loss of $514 million, while chicken earned $405 million.

For fiscal 2027, Tyson expects adjusted operating income of $1.7 billion to $2.15 billion and sales 3.5% to 5.5% lower than fiscal 2026 on a comparable 52-week basis, mainly because of smaller beef volumes from restructuring its plant network and tight cattle supplies. Free cash flow for fiscal 2026 rose $486 million to $1.66 billion, and the board raised the quarterly dividend to 52 cents a share from 51 cents.

Chief Executive Jeff Schomburger said the year reflected “the strength of our diversified multiprotein model.” The company did not give a reason for the share move.

…

That’s the story. … Thank you for listening to Cedar Global Markets. We’re supported by our partners, and you can learn more about the partner featured on this page. We’ll see you next time.

TradingView partner
Tags: Homepage Latest BriefingMarket Movers

Related Posts

Grid of 100 squares representing $100 in State Street's SPDR S&P 500 ETF as of Nov. 13, 2026, with about 15 squares colored for chip stocks: Nvidia $6.04, Broadcom, Micron and AMD together $5.21, and 15 other chipmakers and chip-equipment makers $3.45, for about $14.70 in all.

Your 401(k) Is Riding on a Handful of Chip Stocks

by Cedar Global Markets
November 16, 2026
0

In a major S&P 500 index fund, about $14.70 of every $100 sits in chip stocks, $6 of...

Bar chart of Summit Therapeutics' daily closing share prices from Monday, Nov. 9, 2026, at $17.84 down to $14.15 on Friday, Nov. 13, then $11.82 at 2:20 p.m. Eastern time on Monday, Nov. 16, down 16.5%, below the stock's lowest close of the past year, $12.43 on Aug. 20, after the FDA rejected its lung cancer drug application.

Summit Therapeutics Sinks 16% After the FDA Rejects Its Lung Cancer Drug Application

by Cedar Global Markets
November 16, 2026
0

Summit Therapeutics fell 16.5% to $11.82 by 2:20 p.m. Eastern after the FDA declined to approve ivonescimab for...

Bar showing UniCredit has secured just under half of Commerzbank's voting rights, above a timeline of approvals for its takeover: filed with EU regulators Oct. 9, European Central Bank approval in October, U.S. Federal Reserve approval in November, unconditional EU approval Nov. 16, and the last approval expected by the end of November.

EU Clears UniCredit’s Takeover of Commerzbank Without Conditions

by Cedar Global Markets
November 16, 2026
0

The European Commission found no competition concerns; UniCredit, which has secured just under half of Commerzbank's voting rights,...

Latest Briefing

Market Glance: Chip Stocks Drag Wall Street Lower Before Nvidia’s Report

November 16, 2026

Your 401(k) Is Riding on a Handful of Chip Stocks

November 16, 2026

Summit Therapeutics Sinks 16% After the FDA Rejects Its Lung Cancer Drug Application

November 16, 2026

Tyson Foods Jumps 6% After Its Year-End Report and a Dividend Increase

November 16, 2026
Next Post
Bar chart of Summit Therapeutics' daily closing share prices from Monday, Nov. 9, 2026, at $17.84 down to $14.15 on Friday, Nov. 13, then $11.82 at 2:20 p.m. Eastern time on Monday, Nov. 16, down 16.5%, below the stock's lowest close of the past year, $12.43 on Aug. 20, after the FDA rejected its lung cancer drug application.

Summit Therapeutics Sinks 16% After the FDA Rejects Its Lung Cancer Drug Application

Cedar Global Markets

Categories
  • Africa
  • Americas
  • Asia-Pacific
  • Banking
  • Business
  • Commodities
  • Economy
  • Energy
  • Europe
  • Global
  • Industry
  • Market Glance
  • Markets
  • Middle East
  • Opinion
  • Policy
  • Technology
  • Trade
[mc4wp_form]

© 2026 Cedar Global Markets  ·  About Us  ·  Contact  ·  Advertise  ·  Partners  ·  Privacy  ·  Terms

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Markets
  • Economy
  • Business
  • Energy
  • Technology
  • Global
    • Middle East
    • Europe
    • Asia-Pacific
    • Americas
    • Africa
  • Opinion
SAVED POSTS

© 2026 Cedar Global Markets